Michel Jean Baptiste, MD
Psychiatry · Woodbridge, CTNPI 1316050792
Payments from drug & device makers
Across 863 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Lundbeck LLC$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Sunovion Pharmaceuticals Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $7K from 21 others
What the payments were for
- Food & beverage$17,08197%
- Education$4473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 148 | $2,411 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 80 | $1,994 |
| Lundbeck LLC | 94 | $1,984 |
| Otsuka America Pharmaceutical, Inc. | 78 | $1,685 |
| Sunovion Pharmaceuticals Inc. | 82 | $1,599 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $1,254 |
| Teva Pharmaceuticals USA, Inc. | 54 | $1,239 |
| Alkermes, Inc. | 50 | $997 |
| Neurocrine Biosciences, Inc. | 47 | $977 |
| Johnson & Johnson | 31 | $567 |
| Avanir Pharmaceuticals, Inc. | 23 | $434 |
| Merck | 22 | $432 |
| Eisai Inc. | 22 | $421 |
| Almatica Pharma LLC | 13 | $315 |
| Axsome Therapeutics, Inc. | 12 | $307 |
| Vanda Pharmaceuticals Inc. | 12 | $278 |
| Idorsia Pharmaceuticals US Inc | 13 | $195 |
| Shire North American Group Inc | 4 | $78 |
| Noven Therapeutics, LLC | 4 | $74 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| Corium, LLC | 2 | $53 |
| Upsher-smith Laboratories LLC | 2 | $46 |
| Currax Pharmaceuticals LLC | 2 | $35 |
| Neuronetics, Inc. | 1 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$17,528 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $226,059 |
| VraylarCariprazine Hcl | 29 | $53,353 |
| CaplytaLumateperone Tosylate | 32 | $52,765 |
| RexultiBrexpiprazole | 17 | $28,018 |
| TrintellixVortioxetine Hydrobromide | 30 | $24,952 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,795 |
| Lurasidone Hcl | 72 | $19,201 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $13,331 |
| Clozapine | 241 | $12,102 |
| Aripiprazole | 99 | $9,509 |
| Divalproex Sodium ErDivalproex Sodium | 227 | $8,639 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $7,511 |
| Loreev XrLorazepam | 16 | $7,470 |
| Divalproex Sodium | 62 | $6,538 |
| Chlorpromazine Hcl | 30 | $6,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $977 | $226,05926 claims |
| AbbVieVraylar | $2,411 | $53,35329 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,994 | $52,76532 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,254 | $32,46245 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,685 | $28,01817 claims |
| Alkermes, Inc.Lybalvi | $997 | $22,79514 claims |
| Axsome Therapeutics, Inc.Auvelity | $307 | $13,33115 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $315 | $8,639123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Woodbridge
- Vladimir CoricNew Haven$133.7M
- Christopher VandyckNew Haven$20.8M
- Bart SloanNorwalk$6.8M
- Adam MeccaNew Haven$5.1M
- David MatuskeyFarmington$3M
- Donald AmmermanDanbury$1.5M
- Mahmoud OkashaNorwich$1.4M
- Gerard SanacoraNew Haven$1.3M
- Jayesh KamathFarmington$1.2M
- Deepak DsouzaWest-Haven$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.